本文仅供中国大陆地区执业的医学药学专业人士参考，如您非前述专业人士，请离开本页面
✩ 本文仅供医疗卫生等专业人士参考
*此文仅用于向医疗卫生专业人士提供科学信息，不代表平台立场
审批编码：PP-BA-CN-4912
获批日期：2024 年 10 月 9 日
内容策划：郭青青
项目审核：曹欢
题图来源：丁香园自制
参考文献
[1] Rudnicka L, et al. European expert consensus statement on the systemic treatment of alopecia areata. J Eur Acad Dermatol Venereol. 2024;38(4):687-94.
[2] 国家药品监督管理局. 【2023-3-25】https://www.nmpa.gov.cn/zwfw/sdxx/sdxxyp/yppjfb/20230325145930100.html
[3] M. Senna, et al. AAD 2024 Abstract #49690.
[4] King B, et al. AAD 2024 Abstract&Poster #52874.
[5] B. King, et al. AAD 2024 Poster #51436
[6] 巴瑞替尼说明书.
[7] King B, et al. Outcomes of Down-Titration in Patients With Severe Scalp Alopecia Areata Treated With Baricitinib: An Update Through Week 152 From BRAVE-AA2. 2023 Fall CDC.
[8] King B, et al. Br J Dermatol. 2023;189(6):666-673.
[9] Senna M, et al. Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2. J Eur Acad Dermatol Venereol. 2024 Mar;38(3):583-593.
[10] Mostaghimi A, et al. Among Scalp Non-responder Patients With Eyebrow/Eyelash Regrowth in the First Year, Continued Treatment With Baricitinib Resulted in Meaningful Scalp Responses for Patients With Severe Alopecia Areata. 2024 AAD. Poster 52898.
